linjc16/ctgov huggingface dataset:
Early Postnatal Management of Gestational Brain Sonographic Malformations.

Study Overview
=================
Brief Summary
-----------------
Gestational sonographic follow up may find some brain malformations. The trial is about to characterize these findings and correlate with the immediate postnatal findings.

Detailed Description
-----------------
Gestational sonographic follow up may find some brain malformations (such as ventricular enlargement, agenesis of corpus callosum, etc.).The trial is about to characterize these findings and correlate with the immediate postnatal findings.

Official Title
-----------------
Early Postnatal Management of Gestational Brain Sonographic Malformations.

Conditions
-----------------
Brain Abnormalities

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All term newborn infants who underwent a neurologic consultation or brain ultrasound. Exclusion Criteria: Prematurity

Ages Eligible for Study
-----------------
Maximum Age: 1 Week

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Brain abnormality<br>Newborn who had any gestational brain sonographic abnormality | Other: No intervention<br>* No intervention<br>|
| No brain abnormality<br>Newborn who did not have any gestational brain sonographic abnormality | Other: No intervention<br>* No intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Any postnatal clinical neurologic or sonographic brain abnormality | Post natal sonographic brain abnormality or clinical neurologic abnormality | 10 years |
Controls for Respiratory Diseases

Study Overview
=================
Brief Summary
-----------------
This is the registry of control participants for patients with various respiratory diseases. We screened healthy volunteers who visited Seoul National Hospital Healthcare System Gangnam Center for routine health check-up, and enrolled patients who agree to participate in the study. The participants undergo baseline questionnaires, provide blood specimen and information of the results of health check-up. We will include participants as controls if they have no significant respiratory symptom and no significant radiographic abnormality. The data from this registry will be compared with those from other registry of various respiratory diseases

Official Title
-----------------
The Registry of Controls for Respiratory Diseases

Conditions
-----------------
Chronic Obstructive Pulmonary Disease, Asthma, Idiopathic Pulmonary Fibrosis, Nontuberculous Mycobacterium Infection, Bronchiectasis, Lung Cancer

Intervention / Treatment
-----------------
* Other: no intervation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 19-90 years old male and female underwent health check-up including chest radiography obtained informed consent Exclusion Criteria: those who showed a significant abnormal finding of chest radiography those who reported a significant respiratory symptoms

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Normal control<br> | Other: no intervation<br>* no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | Death | 20 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hospitalization | All cause hospitalization | 20 years | 
| Respiratory hospitalization | Hospitalization from respiratory causes | 20 years | 
| Respiratory diseases diagnosis | Respiratory diseases diagnosis | 20 years |
SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function

Study Overview
=================
Brief Summary
-----------------
HIV infected subjects receiving antiretroviral treatment for greater than 6 years with be evaluated for clinical lipoatrophy and mitochondrial function after switching nucleoside analogues from stavudine (d4T) to tenofovir treatment and after 4. Hypothesis: Tenofovir therapy will increase peripheral fat content as assessed by DEXA and mitochondrial function at 48 weeks.

Detailed Description
-----------------
HIV infected subjects receiving antiretroviral treatment (lopinavir/ritonavir, stavudine, and lamivudine) for greater than 6 years through the Abbott M97-720 protocol with be evaluated for clinical lipoatrophy and mitochondrial function prior to switching nucleoside analogues from stavudine (d4T) to tenofovir and after 48 weeks or tenofovir treatment. Subjects with or without lipoatrophy are eligible for the study. Adipose tissue biopsies to measure mitochondrial function, metabolic laboratory tests, and DAXA scans and clinical evaluations of lipodystrophy will be performed at Entry and after 48 weeks of tenofovir treatment.

Official Title
-----------------
SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial

Conditions
-----------------
HIV Infection

Intervention / Treatment
-----------------
* Drug: Nucleoside analogue switch


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HIV infection Receiving Kaletra, stavudine, and lamivudine for greater than 6 years (through Abbott M97-720 study) Planning to switch from stavudine to tenofovir Exclusion Criteria: Will continue to receive stavudine
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Nucleoside analogue switch|stavudine switched to tenofovir|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lipoatrophy, Mitochondrial function, Nucleoside analogue switch, Treatment Experienced
HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia

Study Overview
=================
Brief Summary
-----------------
To compare the antitumor efficacy and toxicity of Idarubicin and cytarabine in combination with or not with infusions of granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells in patients with newly diagnosed high-risk acute myeloid leukemia (AML).

Official Title
-----------------
HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia

Conditions
-----------------
Acute Myeloid Leukemia

Intervention / Treatment
-----------------
* Drug: idarubicin
* Biological: microtransplantation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Having signed informed consent Diagnosis was based on the French-American-British (FAB) and WHO criteria. Age ≥ 7 years old Age < 60 years old Exclusion Criteria: 1.Patients with a blast crisis of chronic myeloid leukemia or acute promyelocytic leukemia

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: idarubicin<br>The patients will receive induction chemotherapy containing standard dose of idarubicin in combination with cytarabine. | Drug: idarubicin<br>* idarubicin 10-12 mg/m2 for three days<br>|
| Experimental: microtransplantation<br>The patients will receive induction chemotherapy containing high dose of idarubicin in combination with cytarabine and follow by infusioning granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells | Biological: microtransplantation<br>* idarubicin 10-12mg/m2 for four days. After chemotherapy infusion granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells following each of three cycles of high dose cytarabine chemotherapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complete remission |  | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| disease-free survival |  | three years | 
| overall survival |  | three years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute Myeloid Leukemia, idarubicin, Microtransplantation
Collecting Dietary Information From People Undergoing Cancer Treatment

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to develop a secure method of collecting dietary and nutritional intake information from people with cancer. The researchers will use this information to learn more about how dietary information may relate to cancer diagnosis and response to treatment, and to identify factors that may lead to higher or lower risk of cancer.

Official Title
-----------------
Prospective, Digitized Dietary Intake Monitoring in Individuals Undergoing Cancer Therapy

Conditions
-----------------
Receiving Allogeneic Hematopoietic Cell Transplants

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is receiving or planning to receive therapy for cancer. Patient (or caregiver) has access to a smartphone on which to run the diet-data application. Patient (or caregiver) has sufficient English proficiency to work with a smartphone app in English Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| establish a prospective database | of nutritional intake data from immunotherapy patients that can be paired with the fecal and blood biospecimens already being collected under other protocols (06-107, 16-834) for the purpose of conducting studying correlations between nutrition, gut microbiome, and clinical outcomes. | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dietary Intake Monitoring, 22-149
Brain-derived Neurotrophic Factor Participates in Visceral Hyperalgesia in Irritable Bowel Syndrome (IBS) Patients

Study Overview
=================
Brief Summary
-----------------
Brain-derived neurotrophic factor (BDNF), originally known to be a member of the nerve growth factor family, has aroused attention as a modulator in visceral hyperalgesia recently. Visceral hypersensitivity is recognized as a clinical hallmark in IBS patients. So in this study, the investigators will focus on the role of BDNF in colonic hyperalgesia in IBS patients.

Official Title
-----------------
Study of Brain-derived Neurotrophic Factor in Visceral Hyperalgesia in IBS Patients

Conditions
-----------------
Irritable Bowel Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with irritable bowel syndrome. Exclusion Criteria: Patients have similar clinical symptoms as IBS, yet there is morphologic changes in the intestine.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| irritable bowel syndrome<br>patients with diarrhea-predominant IBS will be enrolled in this group. | |
| control group<br>patients with colon cancer or colon polyp will be enrolled as control group. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IBS, BDNf, visceral hypersensitivity
Bacterial and Antimicrobial Susceptibility Profile and the Prevalence of Different Sites of Infection(BASPP)

Study Overview
=================
Brief Summary
-----------------
Positive results of bacterial culture are analyzed comprehensively in Shengjing Hospital of China Medical University in recent 3 years（between 2015- 2017）

Official Title
-----------------
Bacterial and Antimicrobial Susceptibility Profile and the Prevalence of Different Sites of Infection in Shengjing Hospital of China Medical University: a Retrospective, Descriptive Study

Conditions
-----------------
Infectious Diseases in Pneumonia,Nephropyelitis,Angiocholitis or Others, Positive Bacterial Cultures Results of the Medical Records

Intervention / Treatment
-----------------
* Other: descriptive study which reviewed the data of patients hospitalized with positive bacterial cultures


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of pneumonia, nephropyelitis, angiocholitis or other infectious diseases Positive results of bacterial cultures in blood, urine, sputum, and secretion The medical records of shengjing hospital of China Medical University from January 2015 to December 2017 Exclusion Criteria: Negative results of bacterial cultures in blood, urine, sputum, and secretion
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: descriptive study which reviewed the data of patients hospitalized with positive bacterial cultures|A retrospective, descriptive study was conducted at shengjing hospital of China Medical University between 2015- 2017. Data regarding bacterial culture isolates, antimicrobial susceptibility spectrum, and the general data of patients with fever or suspicion of sepsis were collected.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bacterial and antimicrobial susceptibility profile | Primary outcome was recording the results of bacterial and antimicrobial susceptibility profile of pneumonia, nephropyelitis, or angiocholitis, measured with statistical methods. | From January 2015 to December 2017 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| patient's critical condition | Secondary outcome was evaluating the patient's critical condition, measured with APACHE (acute physiology and chronic health evaluation) II score. | From January 2015 to December 2017 |
The Relevance of Performing Lumbar Puncture in Infants Aged 3 to 12 Months With First Episode of Febrile Convulsion

Study Overview
=================
Brief Summary
-----------------
The actual recommendations for infants aged 3 to 12 months presented with first episode of Febrile Convulsions highly recommend performing lumbar puncture in order to rule out Bacterial Meningitis. On the other hand, recent studies in the era of anti Pneumococcal vaccination arise the question if in the presence of a normal physical examination those recommendations are still relevant. The purpose of this study is to summarized retrospectively the clinical records of all the infants admitted to the pediatric wards in the ten years period since 2000 to 2010 in order to record the incidence of Bacterial Meningitis among infants admitted with the First episode of Febrile Convulsions.

Detailed Description
-----------------
Demographic data, including ethnic origin, age an gender will be recorded. The type of Convulsions (Simple or Complex), duration, and time since the fever was noticed will be also recorded. Another data that will be summarized included: previous antibiotic treatment, physical examination with special emphasis on neurological examination and meningeal signs, routine laboratory analysis including blood count and cerebrospinal fluid (CSF) results and the final diagnosis including the cause of fever.

Conditions
-----------------
Febrile Convulsions

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Infants aged 3 to 12 months who presents with First Episode of Febrile Convulsions during the period 1/1/2000 until 31/12/2010 Exclusion Criteria: infants with previous neurological diseases, or recent neurological disease that are not included in the characteristics of Febrile Convulsion

Ages Eligible for Study
-----------------
Minimum Age: 3 Months
Maximum Age: 12 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Infants with first episode of Febrile Convlusions<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with abnormal lumbar puncture | The number of patients aged six months to one year that underwent lumbar puncture when they were admitted with simple febrile convulsions | One year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Infants
Serum Hs-CRP in Periodontitis Patients With or Without Diabetes

Study Overview
=================
Brief Summary
-----------------
the aim of this study was to assess serum levels of high sensitivity c reactive protein in periodontitis patients with and without type 2 diabetes in a trial to analyze its prognostic effect following non-surgical periodontal therapy.

Detailed Description
-----------------
Periodontitis and diabetes are chronic disorders with a two-way correlation as they can both stimulate an inflammatory response with subsequent formation of inflammatory mediators and cytokines. C reactive protein is an inflammatory plasma marker having a role in the systemic reaction to inflammation. thus, our aim in the current study was to evaluate serum levels of high sensitivity c reactive protein in periodontitis patients with and without type 2 diabetes in a trial to analyze its prognostic effect following non-surgical periodontal therapy. A total of 60 patients were enrolled in this study. ELISA was used for determination of hs- CRP. Non- surgical periodontal therapy was carried out for all periodontitis patients.

Official Title
-----------------
Prognostic Value of Serum Hs-CRP in Periodontitis Patients With or Without Type 2 Diabetes Following Non-surgical Periodontal Therapy

Conditions
-----------------
Periodontal Disease, Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Procedure: Scaling and root planing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diabetic patients type 2 Periodontitis patients Exclusion Criteria: Smokers Pregnant females
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Periodontitis patients with diabetes type 2<br>scaling and root planing was administered to all patients. Serum samples were collected before and after treatment to assess hs-CRP levels. Glycated hemoglobin was measured before and after treatment | Procedure: Scaling and root planing<br>* Supra and subgingival scaling and root planing.<br>|
| Experimental: Periodontitis patients<br>scaling and root planing will be done to periodontitis patients. Serum samples were collected before and after treatment to assess hs-CRP levels. | Procedure: Scaling and root planing<br>* Supra and subgingival scaling and root planing.<br>|
| No Intervention: Healthy control group<br>We measured serum levels of hs-CRP in all healthy control subjects | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clinical attachment level | gain in clinical attachment level | 3 months |
Neopterin in Acute Coronary Syndrome Patients

Study Overview
=================
Brief Summary
-----------------
Measurement of neopterin in ACS patients

Detailed Description
-----------------
Detect level of neopterin in ACS patients to detect whether there is relation or not between ACS and neopterin Detection of relation between neopterin and cardiac enzymes as CK and troponine in ACS patients Detect relation between neopterin level and in hospital events

Official Title
-----------------
Neopterin in Acute Coronary Syndrome Patients

Conditions
-----------------
Neopterin in Acute Coronary Syndrome Patients

Intervention / Treatment
-----------------
* Other: Blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patient of sample size admitted to cardiology departmentof Assiut university hospital with : Acute typical chest pain Positive cardiac enzymes ECG show recent ischemic changes ECHO show SWMA Exclusion Criteria: Patients not fulfill inclusion criteria. Patients with other diseases which may cause increase of neopterin level as viral infections, intracellular bacteria or parasites infections, certain malignancies, allograft rejection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Blood sample|Blood samples will obtained for measurement of neopterin level through ELIZA|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To detect whether there is association between neopterin and ACS or not | To detect whether there is association between neopterin and ACS or not | 72 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detection of relation between neopterin and cardiac enzymes as CK and troponine in ACS and detection of relation between neopterin level and in hospital events | Detection of relation between neopterin and cardiac enzymes as CK and troponine in ACS and detection of relation between neopterin level and in hospital events | 72 hours |